All contributors
Onconephrology contributor
Abudayyeh, Ala
Primarily Anticancer drug nephrotoxicity#29 of 46 recognizedHonor roll
- #4 in Checkpoint-inhibitor kidney injury
33
Clinical papers
1,543
Citations (iCite)
3 / 15
First / senior author
2014–2026
Active years
Output over time
Clinical corpus papers per year — peak 5 in 2021, 2024, 2026.
- 2014: 1 paper
- 2016: 1 paper
- 2017: 1 paper
- 2019: 2 papers
- 2020: 4 papers
- 2021: 5 papers
- 2022: 3 papers
- 2023: 3 papers
- 2024: 5 papers
- 2025: 3 papers
- 2026: 5 papers
20142026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Anticancer drug nephrotoxicity17
Checkpoint-inhibitor kidney injury15
Onco-nephrology (general)9
Myeloma cast nephropathy4
MGRS & paraprotein kidney disease3
Cellular therapy renal effects2
Frequent co-authors
Other recognized contributors who most often share corpus papers with Abudayyeh (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Abudayyeh among the leading contributors (clinical-paper count on that agent).
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.